ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

Maryam Nemati Shafaee, MD
Published: Wednesday, Jul 18, 2018



Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

In the PERSEPHONE trial, the investigators looked at disease-free survival in women with early-stage HER2-positive breast cancer who would need adjuvant trastuzumab (Herceptin). Twelve months of adjuvant trastuzumab was compared with 6 months of adjuvant trastuzumab to assess whether 9 doses was noninferior to 18 doses, says Shafaee.

The trial reported noninferiority with 6 months of adjuvant trastuzumab, which has a very high clinical impact, explains Shafaee. Shafaee recently saw a patient with mild cardiomyopathy who was being treated with adjuvant trastuzumab. The patient’s ejection fraction recovered, following 9 doses of trastuzumab. Following the results of the trial, they considered stopping therapy after 9 doses. Shafaee underscores that this is not yet included in the NCCN guidelines, so more data are needed before straying from the current standard 12 months of therapy.


Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

In the PERSEPHONE trial, the investigators looked at disease-free survival in women with early-stage HER2-positive breast cancer who would need adjuvant trastuzumab (Herceptin). Twelve months of adjuvant trastuzumab was compared with 6 months of adjuvant trastuzumab to assess whether 9 doses was noninferior to 18 doses, says Shafaee.

The trial reported noninferiority with 6 months of adjuvant trastuzumab, which has a very high clinical impact, explains Shafaee. Shafaee recently saw a patient with mild cardiomyopathy who was being treated with adjuvant trastuzumab. The patient’s ejection fraction recovered, following 9 doses of trastuzumab. Following the results of the trial, they considered stopping therapy after 9 doses. Shafaee underscores that this is not yet included in the NCCN guidelines, so more data are needed before straying from the current standard 12 months of therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x